We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a new Level
News

Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a new Level

Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a new Level
News

Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a new Level

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a new Level"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Shanghai ChemPartner Co., Ltd. has announced that it has moved its drug discovery collaboration with ELARA Pharmaceuticals to a new level.

ChemPartner will provide fully integrated services in the areas of DMPK, pharmacology and toxicology for ELARA's lead oncology programs. Members of the joint project team from both sides will work closely together to design and execute a drug screening cascade.

"This new relationship is a natural result of the high quality services provided by ChemPartner," commented Dr. Joe Lewis, CEO and a founder of ELARA Pharmaceuticals.

"The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new integrated relationship will enable ELARA to further leverage ChemPartner's strong R&D capabilities from discovery to early development phase. We anticipate a stronger strategic partnership down the road as our program progresses."

"We are very pleased to see that our services helped ELARA turn innovative research at a renowned academic institution into a venture funded drug discovery company," said Michael Hui, founder and CEO of ChemPartner. "Our partnership demonstrates the strength of ChemPartner's innovation driven and fully integrated R&D service platform."
Advertisement